Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 22 May 2024
Setmelanotide for treating obesity caused by LEPR or POMC deficiency (HST21)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 6 July 2022